These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 26571844

  • 1. [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
    Protsenko SA, Rudakova AV.
    Vopr Onkol; 2015; 61(4):676-80. PubMed ID: 26571844
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J, Tien Ho P, Xiang P, Sugay A, Abdel-Sattar M, Wilson L.
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [Abstract] [Full Text] [Related]

  • 3. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 4. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [Abstract] [Full Text] [Related]

  • 5. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J, Bagust A, Boland A, Dwan K, Beale S, Hockenhull J, Proudlove C, Dundar Y, Richardson M, Dickson R, Mullard A, Marshall E.
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
    Lee VW, Schwander B, Lee VH.
    Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
    [Abstract] [Full Text] [Related]

  • 7. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M, Okamoto I, Nakagawa K.
    Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S, Ye M, Ding L, Tan F, Fu J, Wu B.
    Oncotarget; 2017 Feb 07; 8(6):9996-10006. PubMed ID: 28036283
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
    Crvenkova S, Ivkovski Lj, Dimovski A, Kaeva B.
    Prilozi; 2012 Feb 07; 33(1):303-11. PubMed ID: 22983065
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
    Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS.
    Korean J Intern Med; 2015 Nov 07; 30(6):891-8. PubMed ID: 26552465
    [Abstract] [Full Text] [Related]

  • 11. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
    Giuliani J, Martelli S, Remo A, Bonetti A.
    Tumori; 2015 Jul 24; 101(4):e115-7. PubMed ID: 25953440
    [Abstract] [Full Text] [Related]

  • 12. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
    Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, Kido K, Iwakami S, Tominaga S, Takahashi K.
    Respir Investig; 2016 Jan 24; 54(1):14-9. PubMed ID: 26718140
    [Abstract] [Full Text] [Related]

  • 13. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.
    J Clin Oncol; 2008 May 20; 26(15):2442-9. PubMed ID: 18458038
    [Abstract] [Full Text] [Related]

  • 14. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
    Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC.
    J Natl Cancer Inst; 2017 Jun 01; 109(6):. PubMed ID: 28376144
    [Abstract] [Full Text] [Related]

  • 15. Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
    Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, Yun T, Kim HT, Lee JS.
    J Clin Pathol; 2011 Nov 01; 64(11):947-52. PubMed ID: 21725039
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.
    Anticancer Res; 2015 Jul 01; 35(7):3885-91. PubMed ID: 26124334
    [Abstract] [Full Text] [Related]

  • 17. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
    Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):839-44. PubMed ID: 16467097
    [Abstract] [Full Text] [Related]

  • 18. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.
    Clin Cancer Res; 2006 Jul 01; 12(13):3908-14. PubMed ID: 16818686
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y, Matsushima Y, Shiroiwa T, Chiba K, Nakanishi Y, Kurokawa T, Urushihara H.
    Lung Cancer; 2015 Oct 01; 90(1):71-7. PubMed ID: 26259876
    [Abstract] [Full Text] [Related]

  • 20. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC, Lim CK, Chang LY, Chen KY, Shih JY, Yu CJ.
    Eur J Cancer; 2019 Sep 01; 119():77-86. PubMed ID: 31425965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.